Related Experiment Video
Updated: Jan 31, 2026

A Modified Method for Heterotopic Mouse Heart Transplantion
Published on: June 23, 2014
Safety and Efficacy of PCSK9 Inhibitors After Heart Transplantation
Yasbanoo Moayedi1, Stella Kozuszko2, Joshua W Knowles3
1Stanford University, Division of Cardiovascular Medicine, Heart Transplantation, Palo Alto, California, USA; Ted Rogers Centre of Excellence in Heart Function, Peter Munk Cardiac Centre, University Health Network, Toronto, Ontario, Canada.
Insights
Dyslipidemia is common after heart transplantation. PCSK9 inhibitors like evolocumab significantly reduced LDL cholesterol in heart transplant recipients, offering a new therapeutic option.
Area of Science:
- Cardiology
- Immunology
- Pharmacology
Background:
- Dyslipidemia frequently complicates heart transplantation.
- Cardiac allograft vasculopathy progression is linked to dyslipidemia.
- Limited data exists on PCSK9 inhibitors in heart transplant recipients.
Observation:
- Six heart transplant patients received PCSK9 inhibitor therapy.
- Evolocumab was administered to the patients.
- LDL cholesterol levels were monitored post-treatment.
Findings:
- A significant reduction of over 70% in LDL cholesterol was observed.
- PCSK9 inhibitors demonstrated potent lipid-lowering effects.
- The treatment was effective in patients with suboptimal LDL despite statin therapy.
Implications:
- PCSK9 inhibitors represent a promising treatment for dyslipidemia in heart transplant patients.
- This therapy may help manage cardiac allograft vasculopathy progression.
- Further research is warranted to confirm safety and efficacy in this population.
Abstract:
Dyslipidemia is common in patients undergoing heart transplantation and is associated with the progression of cardiac allograft vasculopathy. Two monoclonal antibodies directed against PCSK9i-evolocumab and alirocumab-are currently available. However, their use, safety and efficacy in the post-transplant setting have not been studied. We present our experience with 6 heart transplant recipients treated with a PCSK9i. A > 70% reduction in LDL-cholesterol was observed after evolocumab therapy. PCSK9 inhibitors are a potentially lipid-lowering therapeutic option for heart transplant patients with suboptimal LDL despite maximal tolerated statin doses.
Related Concept Videos
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Survey Safety
Eukaryotic Transcription Inhibitors
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
Self-Efficacy
Household Wiring And Electrical Safety
Anatomy of the Heart

